Dr. Miron on impact of upfront chemo choice on second-line immunotherapy in bladder cancer

Video

First study author Benjamin Miron, MD, a second-year hematology/oncology fellow at Fox Chase Cancer Center, discusses a study of real-world data that explored the influence of first-line chemotherapy choice on overall survival (OS) outcomes in patients with advanced urothelial carcinoma who received immunotherapy in the second-line setting.

Miron et al specifically compared the choice between frontline cisplatin plus gemcitabine versus frontline carboplatin plus gemcitabine. Although there was a numerical benefit favoring cisplatin, the results showed that the specific choice of frontline platinum therapy did not result in a significant difference in OS in patients subsequently receiving second-line immunotherapy.

The results were shared during the 2021 ASCO Annual Meeting (J Clin Oncol 39, 2021 [suppl 15; abstr 4535]. doi:10.1200/JCO.2021.39.15_suppl.4535). Miron conducted the study with other Fox Chase colleagues, including Elizabeth Handorf, PhD, an associate professor in the Cancer Prevention and Control Program, and Daniel M. Geynisman, MD, an associate professor in the Department of Hematology/Oncology.

Recent Videos
Alexander Pastuszak, MD, PhD: Is hormone therapy safe after prostate cancer radiotherapy?
Refining prostate cancer therapy strategy to address RAPTOR findings
Considering patient-reported outcomes in kidney cancer care, with Nicholas Zaorsky, MD, PhD
Soumyajit Roy, MS, MBBS: The effect of prostate cancer patient history in RAPTOR
 Nicholas Zaorsky, MD, MS: Protecting kidney function after local renal cell carcinoma therapy
Nicholas van AS, MD, MBBCH: The case for SBRT as a standard of care for localized prostate cancer
Pierre Blanchard, MD, PhD: What can hydrogel space provide to optimal prostate cancer care?
Savita Dandapani, MD, PhD: Findings from the phase 2 SHARP trial
Related Content
© 2024 MJH Life Sciences

All rights reserved.